Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Capital Employed (2020 - 2025)

Keros Therapeutics' Return on Capital Employed history spans 6 years, with the latest figure at 0.13% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 50.0% year-over-year to 0.13%; the TTM value through Dec 2025 reached 0.13%, up 50.0%, while the annual FY2025 figure was 0.15%, 60.0% up from the prior year.
  • Return on Capital Employed reached 0.13% in Q4 2025 per KROS's latest filing, up from 0.06% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.13% in Q4 2025 to a low of 0.52% in Q4 2023.
  • Average Return on Capital Employed over 5 years is 0.29%, with a median of 0.37% recorded in 2022.
  • Peak YoY movement for Return on Capital Employed: fell -19bps in 2022, then surged 50bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.24% in 2021, then plummeted by -79bps to 0.44% in 2022, then dropped by -20bps to 0.52% in 2023, then rose by 30bps to 0.37% in 2024, then surged by 135bps to 0.13% in 2025.
  • Per Business Quant, the three most recent readings for KROS's Return on Capital Employed are 0.13% (Q4 2025), 0.06% (Q3 2025), and 0.0% (Q2 2025).